Young-age prostate cancer

Affiliations


Abstract

Although prostate cancer is a disease of the elderly, its diagnosis is not uncommonly made in men younger than 55 years. Both ethnic, familial and genetic factors play a role in the early onset of prostate cancer, but the biology, particularly of low-grade prostate cancers detected at young age is not well understood. Autopsy studies have shown a high prevalence of Gleason score 6 prostate cancers in men under 55 years, but mortality of prostate cancer at this young age is almost negligible. Recently, a number of susceptibility genes such as BRCA2 and HOXB13 were reported, each with their own specific biological and histopathology features. In this review, we provide an update on the most recent findings in young-age prostate cancer.

Keywords: EPIDEMIOLOGY; GENETICS; UROGENITAL PATHOLOGY.


Similar articles

HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk.

Laitinen VH, Wahlfors T, Saaristo L, Rantapero T, Pelttari LM, Kilpivaara O, Laasanen SL, Kallioniemi A, Nevanlinna H, Aaltonen L, Vessella RL, Auvinen A, Visakorpi T, Tammela TL, Schleutker J.Cancer Epidemiol Biomarkers Prev. 2013 Mar;22(3):452-60. doi: 10.1158/1055-9965.EPI-12-1000-T. Epub 2013 Jan 4.PMID: 23292082 Clinical Trial.

Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.

Kote-Jarai Z, Mikropoulos C, Leongamornlert DA, Dadaev T, Tymrakiewicz M, Saunders EJ, Jones M, Jugurnauth-Little S, Govindasami K, Guy M, Hamdy FC, Donovan JL, Neal DE, Lane JA, Dearnaley D, Wilkinson RA, Sawyer EJ, Morgan A, Antoniou AC, Eeles RA; UK Genetic Prostate Cancer Study Collaborators, and the ProtecT Study Group.Ann Oncol. 2015 Apr;26(4):756-761. doi: 10.1093/annonc/mdv004. Epub 2015 Jan 16.PMID: 25595936

Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).

Russo AL, Chen MH, Aizer AA, Hattangadi JA, D'Amico AV.BJU Int. 2012 Oct;110(7):973-9. doi: 10.1111/j.1464-410X.2012.11470.x.PMID: 22954029

[Update on genetic predisposition to prostate cancer].

Cussenot O, Cancel-Tassin G.Bull Cancer. 2015 Jan;102(1):53-6. doi: 10.1016/j.bulcan.2014.12.007. Epub 2014 Dec 29.PMID: 25609482 Review. French.

Screening for familial and hereditary prostate cancer.

Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, D'Amico AV, Buxbaum S, Isaacs WB, Loeb S, Moul JW, Powell I.Int J Cancer. 2016 Jun 1;138(11):2579-91. doi: 10.1002/ijc.29949. Epub 2016 Feb 5.PMID: 26638190 Review.


Cited by

Age- and Stage-Dependent Prostate Cancer Aggressiveness Associated with Differential Notch Signaling.

Orzechowska MJ, Anusewicz D, Bednarek AK.Int J Mol Sci. 2022 Dec 22;24(1):164. doi: 10.3390/ijms24010164.PMID: 36613607 Free PMC article.

Liquid Biopsy in Diagnosis and Prognosis of Non-Metastatic Prostate Cancer.

Rzhevskiy AS, Kapitannikova AY, Butnaru DV, Shpot EV, Joosse SA, Zvyagin AV, Ebrahimi Warkiani M.Biomedicines. 2022 Dec 2;10(12):3115. doi: 10.3390/biomedicines10123115.PMID: 36551871 Free PMC article. Review.

Prostate cancers in men under the age of 50: about a series in Togo, Sub-Saharan Africa.

Darré T, Djiwa T, Kpatcha TM, Padja E, Napo-Koura G, Darre T.BMC Cancer. 2022 Dec 21;22(1):1341. doi: 10.1186/s12885-022-10425-6.PMID: 36544122 Free PMC article.

A young patient with prostatic carcinoma with testicular metastasis.

Balagobi B, Gobishangar S, Sarma ST, Brammah RT, Jenil A.Int J Surg Case Rep. 2022 Oct;99:107653. doi: 10.1016/j.ijscr.2022.107653. Epub 2022 Sep 13.PMID: 36115121 Free PMC article.

Outcome of 177Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer.

Mader N, Groener D, Tselis N, Banek S, Nagarajah J, Grünwald F, Sabet A.Cancers (Basel). 2021 Aug 20;13(16):4193. doi: 10.3390/cancers13164193.PMID: 34439347 Free PMC article.